Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:02PM EST
Pre-market:
| Previous close | 81.38 |
| Open | 81.10 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's range | 80.81 - 82.16 |
| 52-week range | 68.44 - 91.40 |
| Volume | |
| Avg. volume | 13,776,317 |
| Market cap | 205.965B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 28.77 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.76 (3.59%) |
| Ex-dividend date | 14 Dec 2021 |
| 1y target est | N/A |
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
KENILWORTH, N.J., January 18, 2022--KEYTRUDA Significantly Improved Overall Survival (OS) in Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
- Business Wire
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
KENILWORTH, N.J. & MIAMI, January 18, 2022--Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
KENILWORTH, N.J., January 10, 2022--KEYTRUDA Showed Significant Improvement in Disease-Free Survival as Adjuvant Treatment for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression
© 2022 Yahoo. All rights reserved.
